Viz.ai has received clearance from the U.S. Food and Drug Administration (FDA) for an algorithm to automatically calculate right-to-left ventricle diameter (RV/LV ratios) of the heart on CT scans.
The algorithm is a new component of the company's Viz PE platform, which is used to identify suspected central and segmental pulmonary emboli in under two minutes, the company said. With the integration of the RV/LV algorithm, the software now includes an automated assessment of potential right ventricle dilation.
Viz PE now includes both detection of clots in the lungs and degree of strain on the right heart, which will enable clinicians to quickly triage patients and treat them appropriately, Viz.ai said.
